免疫检查点及其抑制剂的发展

摘要/Abstract

中图分类号:

R730

于颖彦. 免疫检查点及其抑制剂的发展[J]. 内科理论与实践, 2022, 17(01): 48-52.

图/表1

表1

肿瘤相关免疫检查点、配体及其表达细胞

T细胞受体	配体表达
T细胞受体	抗原提呈细胞	肿瘤细胞	其他细胞
CTLA4（CD152）	CD80（B7-1）、CD86（B7-2）
PD1（CD279）		PD-L1（CD274）、PD-L2（B7-DC）
TIM-3（HAVCR2）	GAL-9	CEACAM1、HMGB1 PS
TIGIT（VSIG9）	CD155（PVR）、CD112（PVRL2）		巨噬细胞
LAG-3（CD223）	MHC-Ⅱ	MHC-Ⅱ、FGL1	肝窦间隙内皮细胞
BTLA	HVEM（TNFRSF14）
VISTA（PD1-H）	VSIG3、PSGL-1、VISTA	VISTA未知	胎盘
未知	B7-H3（CD276）/B7-H4（B7S1）	B7-H3（CD276）/B7-H4（B7S1）	内皮细胞
未知		SIGLEC15	肿瘤浸润髓细胞破骨细胞,巨噬细胞
AHR	IDO1代谢物KYN	IDO1代谢物KYN	单核细胞,巨噬细胞

表1

参考文献29

[1]	Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013, 13(4): 227-242. doi:10.1038/nri3405 URL
[2]	Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma[J]. J Dtsch Dermatol Ges, 2011, 9(4): 277-286.
[3]	Zhai Y, Moosavi R, Chen M. Immune checkpoints, a novel class of therapeutic targets for autoimmune diseases[J]. Front Immunol, 2021, 12: 645699. doi:10.3389/fimmu.2021.645699 URL
[4]	Xiang Z, Zhou Z, Song S, et al. Dexamethasone suppresses immune evasion by inducing GR/STAT 3 mediated downregulation of PD-L1 and IDO1 pathways[J]. Oncogene, 2021, 40(31): 5002-5012. doi:10.1038/s41388-021-01897-0pmid:34175886
[5]	Zahavi DJ, Weiner LM. Targeting multiple receptors to increase checkpoint blockade efficacy[J]. Int J Mol Sci, 2019, 20(1): 158. doi:10.3390/ijms20010158 URL
[6]	Hernández áP, Juanes-Velasco P, Landeira-Viñuela A, et al. Restoring the immunity in the tumor microenvironment: insights into immunogenic cell death in onco-therapies[J]. Cancers (Basel), 2021, 13(11): 2821. doi:10.3390/cancers13112821 URL
[7]	Muller AJ, Manfredi MG, Zakharia Y, et al. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond[J]. Semin Immunopathol, 2019, 41(1): 41-48. doi:10.1007/s00281-018-0702-0 URL
[8]	Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy[J]. Nat Med, 2019, 25(4): 656-666. doi:10.1038/s41591-019-0374-xpmid:30833750
[9]	Ren X. Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle[J]. Cancer Biol Med, 2019, 16(2): 205-210. doi:10.20892/j.issn.2095-3941.2018.0141 URL
[10]	Mathieu L, Shah S, Pai-Scherf L, et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer[J]. Oncologist, 2021, 26(5): 433-438. doi:10.1002/onco.13752 URL
[11]	Kaplon H, Reichert JM. Antibodies to watch in 2019[J]. MAbs, 2019, 11(2): 219-238. doi:10.1080/19420862.2018.1556465 URL
[12]	Keam SJ. Toripalimab: first global approval[J]. Drugs, 2019, 79(5): 573-578. doi:10.1007/s40265-019-01076-2 URL
[13]	Zhang Y, Li X, Sun Y, et al. Pharmacokinetics of S-epacadostat, an indoleamine 2,3-dioxygenase 1 inhibitor, in dog plasma and identification of its metabolitesin vivoandin vitro[J]. Biomed Chromatogr, 2021, 35(12); e5226. doi:10.1002/bmc.5226pmid:34388261
[14]	Shi JG, Bowman KJ, Chen X, et al. Population pharmacokinetic and pharmacodynamic modeling of epacadostat in patients with advanced solid malignancies[J]. J Clin Pharmacol, 2017, 57(6): 720-729. doi:10.1002/jcph.855 URL
[15]	Yu Y. Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers[J]. Cancer Biol Med, 2021, 18 (4): 944-948. doi:10.20892/j.issn.2095-3941.2021.0491 URL
[16]	Fattakhova E, Hofer J, DiFlumeri J, et al. Identification of the FDA-approved drug pyrvinium as a small-molecule inhibitor of the PD-1/PD-L1 interaction[J]. ChemMedChem, 2021, 16(18): 2769-2774. doi:10.1002/cmdc.202100264 URL
[17]	Han N, Hwang W, Tzelepis K, et al. Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies[J]. Sci Adv, 2021, 7(27): eabh3032. doi:10.1126/sciadv.abh3032 URL
[18]	Bronte G, Verlicchi A, De Matteis S, et al. Circulating myeloid-derived suppressive-like cells and exhausted immune cells in non-small cell lung cancer patients treated with three immune checkpoint inhibitors[J]. Front Immunol, 2021, 12: 672219. doi:10.3389/fimmu.2021.672219 URL
[19]	Takahashi A, Namikawa K, Ogata D, et al. Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma[J]. J Dermatol, 2020, 47(11): 1267-1275. doi:10.1111/1346-8138.15521 URL
[20]	Gaudreau PO, Lee JJ, Heymach JV, et al. Phase Ⅰ/Ⅱ trial of immunotherapy with durvalumab and tremelimumab with continuous or intermittent MEK inhibitor selumetinib in NSCLC[J]. Clin Lung Cancer, 2020, 21(4): 384-388. doi:10.1016/j.cllc.2020.02.019 URL
[21]	Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma[J]. J Clin Oncol, 2017, 35(34): 3851-3858. doi:10.1200/JCO.2016.72.1985pmid:28678668
[22]	McGregor BA, Campbell MT, Xie W, et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies[J]. Cancer, 2021, 127(6): 840-849. doi:10.1002/cncr.33328 URL
[23]	Ebata T, Shimizu T, Fujiwara Y, et al. Phase Ⅰ study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours[J]. Invest New Drugs, 2020, 38(2): 468-477. doi:10.1007/s10637-019-00787-3 URL
[24]	Jung KH, LoRusso P, Burris H, et al. Phase Ⅰ study of the indoleamine 2,3-dioxygenase 1(IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors[J]. Clin Cancer Res, 2019, 25: 3220-3228. doi:10.1158/1078-0432.CCR-18-2740 URL
[25]	Hollebecque A, Chung HC, de Miguel MJ, et al. Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors[J]. Clin Cancer Res, 2021, 27(23): 6393-6404. doi:10.1158/1078-0432.CCR-21-0261pmid:34465599
[26]	Atkinson V, Khattak A, Haydon A, et al. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma[J]. J Immunother Cancer, 2020, 8(2): e001681. doi:10.1136/jitc-2020-001681 URL
[27]	De Luca AJ, Lyons AB, Flies AS. Cytokines: signalling improved immunotherapy?[J]. Curr Oncol Rep, 2021, 23(9): 103. doi:10.1007/s11912-021-01095-x URL
[28]	Shibata Y, Murakami S, Kato T. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors[J]. Expert Opin Drug Saf, 2021, 20(5): 537-547. doi:10.1080/14740338.2021.1898584 URL
[29]	Cunningham M, Iafolla M, Kanjanapan Y, et al. Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy[J]. PLoS One, 2021, 16(6): e0253070. doi:10.1371/journal.pone.0253070 URL

免疫检查点及其抑制剂的发展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表1

参考文献29

相关文章15

编辑推荐

Metrics

本文评价

[1]	朱芳　徐喆　王先明　宋达疆　李赞　何建怀　屈洪波.乳腺癌根治术后即刻行扩大背阔肌肌皮瓣乳房再造50例分析[J]. 组织工程与重建外科杂志, 2022, 18(5): 377-.
[2]	刘淼, 沈燕, 傅晓红, 胡姣姣, 陈庆庆, 应涛.常规超声和超声造影检查不同大小病灶乳腺癌的比较研究[J]. 外科理论与实践, 2022, 27(3): 229-233.
[3]	钟民衎　崔锡炜　顾斌　李青峰　王智超.Ⅰ型神经纤维瘤病相关眼眶-眶周型丛状神经纤维瘤的临床治疗进展[J]. 组织工程与重建外科杂志, 2022, 18(2): 179-.
[4]	潘睿忻综述, 陈小松, 沈坤炜审校.循环肿瘤DNA和循环肿瘤细胞检测乳腺癌微小残留病灶的研究[J]. 外科理论与实践, 2022, 27(05): 463-467.
[5]	马雪菲, 王学锋, 王侃侃.浆细胞瘤变异体易位1和MYC基因在泛癌中的表达及生存期预测价值分析[J]. 诊断学理论与实践, 2022, 21(04): 490-496.
[6]	何新, 陈慧, 冯炜炜.机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546.
[7]	车稳, 柳蒋书, 陈晓炎, 王朝夫, 袁菲, 王璇.肺混合性鳞状细胞和腺性乳头状瘤2例临床病理特征及冷冻切片病理诊断误诊分析[J]. 诊断学理论与实践, 2022, 21(04): 476-481.
[8]	李为光, 孙蕴伟, 孙菁, 张本炎, 王华枫, 钱爱华.直径≤1 cm的直肠神经分泌肿瘤2种内镜治疗方法的比较[J]. 内科理论与实践, 2022, 17(04): 289-294.
[9]	郭良奇, 严志龙, 张谋成.腹腔镜经胃腔手术治疗胃黏膜下肿瘤和早期胃癌[J]. 外科理论与实践, 2022, 27(04): 380-383.
[10]	汤钊猷.中华哲学思维对肝癌治疗的启迪[J]. 外科理论与实践, 2022, 27(02): 93-94.
[11]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜.肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[12]	管涛(综述), 张倜, 王鲁(审校).肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184.
[13]	杨伯文, 姜美娇, 陈慧.超声IOTA简单法鉴别诊断卵巢肿瘤良恶性的临床研究[J]. 诊断学理论与实践, 2022, 21(01): 74-79.
[14]	史逸华, 吉顺荣, 徐晓武, 虞先濬.保留功能的微创胰腺肿瘤剜除术技术要点及思考[J]. 外科理论与实践, 2022, 27(01): 14-18.
[15]	李骥, 傅德良, 倪泉兴.胰腺囊性肿瘤的手术干预决策与局部剜除术[J]. 外科理论与实践, 2022, 27(01): 19-21.